间充质干细胞（MSC）用于治疗各种疾病的用途正在研究中，但其在宫颈癌中的用途尚未得到充分研究。在这里，我们检查了收集的 MSC 条件培养基 (CM) 与 HeLa 细胞系共培养 24、48、1 至 5 天后对外周血单核细胞 (PBMC) 的凋亡、增殖和细胞因子产生的影响。分别通过 CFSE 测定、流式细胞术和实时 PCR 检测 72 小时。我们发现，在 MSC 培养的第三天收集的 CM 显着增加了 PBMC 的增殖，并在 48 小时后降低了 HeLa 细胞的增殖。 CM 对细胞死亡没有显着影响，但显着增加 HeLa 细胞的凋亡。实时 PCR 分析表明，与 HeLa 细胞共培养 48 小时后，MSC 培养第三天收集的 CM 的存在导致 PBMC 中 IL2、IFN-γ 和 TGF-β 基因表达显着增加。前面提到的数据表明，MSC-CM 在培养 HeLa 细胞的同时可以诱导 PBMC 的生长和耐力。这一观察结果表明它们作为宫颈癌细胞免疫调节疗法的巨大潜力。然而，为了全面理解涉及 PBMC 和间充质干细胞的基本机制并完善治疗策略，还需要进行额外的研究。© 作者，获得 Springer Nature B.V. 2024 的独家许可。Springer Nature 或其许可方（例如协会或其他机构）合作伙伴）根据与作者或其他权利持有人的出版协议拥有本文的专有权；作者对本文已接受的手稿版本的自行存档仅受此类出版协议和适用法律的条款的约束。

The use of mesenchymal stem cells (MSCs) for the treatment of various diseases is being investigated, however, their use in cervical cancer has not been well-studied. Here, we examined the impact of collected MSC-conditioned medium (CM) on 1 to 5 days on apoptosis, proliferation, and cytokine production of peripheral blood mononuclear cells (PBMCs) when co-cultured alongside the HeLa cell line for 24, 48, and 72 h by CFSE assay, flow cytometry, and real-time PCR, respectively. We found that CMs collected on the third day of MSCs culture significantly increased the proliferation of PBMCs and decreased the proliferation of HeLa cells after 48 h. CMs showed no significant effects on cell death, whereas it significantly increased the apoptosis of HeLa cells. Real-time PCR analysis showed that the presence of CM collected on the third day of MSCs culture caused a significant increase in the gene expression of IL2, IFN-γ, and TGF-β in PBMCs after 48 h co-culture with HeLa cells. The data mentioned earlier demonstrate that MSC-CM can induce the growth and endurance of PBMCs while concurrently culturing HeLa cells. This observation indicates their promising potential as immunomodulatory therapies for cervical cancer cells. Nevertheless, additional investigation is imperative to comprehensively comprehend the fundamental mechanisms and refine therapeutic strategies involving PBMCs and mesenchymal stem cells.© The Author(s), under exclusive licence to Springer Nature B.V. 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.